Linda Gieschen is an accomplished life sciences executive with over three decades of experience in biopharmaceutical program management, regulatory operations, and technical development. She currently serves as Vice President of Program Management at Sydnexis, Inc., where she oversees a pediatric Phase 3 clinical trial, managing regulatory and clinical operations, corporate timelines, budgeting, and data room administration.

In addition, Linda is the founder and President of Cascade Pharma Consulting, where since 2010 she has provided strategic and operational expertise to a range of biotech companies. Her consultancy spans clinical and nonclinical study oversight, CMC coordination, regulatory submissions, budget planning, and vendor management.

Previously, Linda held key leadership roles at PvP Biologics (acquired by Takeda), Meritage Pharma (Acquired by Shire), Verus Pharmaceuticals, and Dura Pharmaceuticals ( acquired by Elan) , contributing to major development programs and successful acquisitions. Her early technical career at Battelle Pacific Northwest Laboratories established her expertise in inhalation toxicology systems and data acquisition technologies.

Linda holds a B.S. from Washington State University (Mathematics).